Approved for use through 073112060. CMB 0851-0031
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent and Trademick Office; U.S. DEPARTMENT OF COMMENT
U.S. Patent AND U.S. DEPARTMENT OF COMMENT
U.S. Patent AND U.S. DEPARTMENT OF COMMENT
U.S. Patent U.S. DEPARTMENT OF COMMENT
U.S. Patent U.S. DEPARTMENT
U.S.

STATEMENT UNDER 37 CFR 3.73(b)	
Applicant/Patent Owner: Purdue Pharma L.P.	
Application No./Patent No.: 10/701,041	Filed/Issue Date: November 4, 2003
Entitled: TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS	
Purdue Pharma L.P. , a Limited Partnership	
	Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is:	
1. X the assignee of the entire right, title, and interest; or	
2. an assignee of less than the entire right, title,	and Interest
The extent (by percentage) of its ownership Interest is% In the patent application/patent identified above by virtue of either:	
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Real, Frame, or for which a copy thereof is attached.	
OR	
B. A chain of title from the Inventor(s), of the patent application/patent identified above, to the current assignee as shown below:	
To: <u>Euro-Celtique S.A.</u> The document was recorded in the United States Patent and Trademark Office at Reel <u>015008</u> , Frame <u>00666</u> , or for which a copy thereof is attached.	
From: <u>Euro-Celtique S.A.</u> To: <u>Purdue Pharma L.P.</u> The document was recorded in the United States Patent and Trademark Office at Reel <u>020227</u> , Frame <u>0311</u> , or for which a copy thereof is attached.	
3. From: To	
The document was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.	
☐ Additional documents in the chain of title are listed on a supplemental sheet.	
☐ Copies of assignments or other documents in the chain of title are attached. [NOTE: A separate copy (i.e., a true copy of the original document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.09]	
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.	
Old (.	April 23, 2009
Signature	Date
Phillip C. Strassburger	(203) 588-7639
Printed or Typed Name	Telephone Number
Vice President, Intellectual Property Counsel	
Title	

This clicition of information is registed by 37 EFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the SEPT OF processor and processor and